Fiche centre
Princess Alexandra Hospital
Woolloongabba — Australia
Essais liés9clinical trials
VilleWoolloongabbalocalisation
PaysAustralialocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05920356
Essais cliniques associés
9| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Sonrotoclax | Cancer | Phase 3 | NCT07277231 | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia | RECRUITING |
| Tacabrutideg | Cancer | Phase 1/2 | NCT05006716 | CaDAnCe-101 — A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | RECRUITING |
| Sotorasib | Cancer | Phase 3 | NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | RECRUITING |
| Acoramidis | Alzheimer | Phase 3 | NCT06563895 | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | RECRUITING |
| bemdaneprocel | Parkinson | Phase 3 | NCT06944522 | exPDite-2 — A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease | RECRUITING |
| Prasinezumab | Parkinson | Phase 3 | NCT07174310 | PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | RECRUITING |
| Fenebrutinib | SEP | Phase 3 | NCT04544449 | FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| CNM-Au8 | SEP | Phase 2/3 | NCT04626921 | VISIONMS-LTE — A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis | COMPLETED |
| CVN424 75 mg | Parkinson | Phase 3 | NCT06553027 | To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | ACTIVE_NOT_RECRUITING |